modernretina.com

Analisi sito web modernretina.com

Modern Retina – Ophthalmology News, Events & Expert Insights

 Generato il Marzo 31 2026 15:12 PM

Statistiche non aggiornate? AGGIORNA !

Il punteggio e 57/100

SEO Content

Title

Modern Retina – Ophthalmology News, Events & Expert Insights

Lunghezza : 60

Perfetto, il tuo title contiene tra 10 e 70 caratteri.

Description

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Lunghezza : 155

Grande, la tua meta description contiene tra 70 e 160 caratteri.

Keywords

Molto male. Non abbiamo trovato meta keywords nella tua pagina. Usa questo generatore gratuito online di meta tags per creare keywords.

Og Meta Properties

Buono, questa pagina sfrutta i vantaggi Og Properties.

Proprieta Contenuto
title Modern Retina
type website
image https://www.modernretina.com/MR_Hover_Logo.jpg
url https://www.modernretina.com/
image:url https://www.modernretina.com/MR_Hover_Logo.jpg
image:width 1200
image:height 630
image:alt Modern Retina – Ophthalmology News, Events & Expert Insights

Headings

H1 H2 H3 H4 H5 H6
1 56 46 4 16 0
  • [H1] Latest News
  • [H2] Conference Coverage
  • [H2] Trending on Modern Retina
  • [H2] Shorts
  • [H2] Podcasts
  • [H2] Videos
  • [H2] Modern Retina Digital Edition
  • [H2] Continuing Medical Education
  • [H2] (CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] (COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches
  • [H2] (CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] (CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME
  • [H2] Practical Approaches to Modern Dry Eye Treatment and Management
  • [H2] (COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management
  • [H2] (COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
  • [H2] (COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes
  • [H2] (COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care
  • [H2] (COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery
  • [H2] 20th Annual Controversies in Modern Eye Care
  • [H2] (CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] (COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience
  • [H2] (COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation
  • [H2] Collaborative Care Symposium
  • [H2] Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
  • [H2] (CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes
  • [H2] (CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management
  • [H2] (CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] (COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success
  • [H2] (COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD
  • [H2] (CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR
  • [H2] Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop
  • [H2] (COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] (CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care
  • [H2] (CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care
  • [H2] Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] Interventional Dry Eye: A Stepwise Treatment & Management Approach
  • [H2] (CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease
  • [H2] (CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management
  • [H2] (CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment
  • [H2] (CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice
  • [H2] (CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP
  • [H2] All News
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H3] Aflibercept to treat ROP in extremely-low-birth-weight children
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
  • [H3] The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD
  • [H3] Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME
  • [H3] The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD
  • [H3] PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice
  • [H3] PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice
  • [H3] Integrating AI to manage DR in a primary care setting
  • [H3] What to expect from virtual AAO 2020
  • [H3] Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion
  • [H3] Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
  • [H3] Ophthalmic drug shortages more frequent, longer lasting than average
  • [H3] Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
  • [H3] Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
  • [H3] NovaBridge, Visara report positive phase 2a results for dual VEGF-A/ANG-2 inhibitor VIS-101
  • [H3] FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
  • [H3] Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa
  • [H3] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H3] Q&A: AI-predicted retinal function shows promise in geographic atrophy
  • [H3] Dr. Mali’s top 5 predictions in ophthalmology for 2026
  • [H3] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H3] Q&A: Gennady Landa, MD, shares clinical insights on the ranibizumab ocular implant
  • [H3] Samsung Bioepis reaches settlement agreement for Eylea (aflibercept) biosimilar
  • [H3] ISS 2026 highlights advances in ophthalmic imaging for retinal practice
  • [H3] American College of Physicians policy paper urges medical community to drop the term “'provider"
  • [H3] PRIMA System: A major step in the battle against GA
  • [H3] MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
  • [H3] Metformin use associated with reduced incidence of intermediate AMD
  • [H3] FDA decision: Carbachol–brimonidine ophthalmic solution approved for presbyopia following BRIO phase 3 results
  • [H3] New optoretinography technique allows direct measurement of rod function in vivo
  • [H3] Navigating geographic atrophy from biomarkers to bilateral therapy
  • [H3] Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
  • [H3] Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast
  • [H3] Long-lived Greenland sharks may point to new approaches for retinal disease
  • [H3] Molecular insights and clinical experience: Extending anti-VEGF durability
  • [H3] Q&A: Evolving approaches to geographic atrophy management
  • [H3] Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
  • [H3] Rates of retinal layer thinning predict visual field progression in glaucoma
  • [H3] First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
  • [H3] FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
  • [H3] 8 things to know about aflibercept 8 mg for retinal vascular disease
  • [H3] A new treatment round-up for AMD and GA
  • [H4] Multi-luminance shape discrimination test shows reliability in low-vision RP population
  • [H4] Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months
  • [H4] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H4] ONL Therapeutics randomizes first European patient in phase 2 GA trial of Xelafaslatide
  • [H5] The Retina TL;DR with Dr. Weng: Moving beyond anti-VEGF with OTX-TKI and Pravin U. Dugel, MD
  • [H5] Pegcetacoplan Does Not Impact Anti-VEGF Treatment in Geographic Atrophy, With Ted Leng, MD, MS
  • [H5] The Retina TL;DR with Dr. Weng: Tracking retinal gene therapies with Arshad M. Khanani, MD, MA, FASRS
  • [H5] Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
  • [H5] The Retina TL;DR with Dr. Weng: Targeting the Fas signaling pathway with David Zacks, MD, PhD
  • [H5] Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases
  • [H5] Management Approaches for Suboptimal Responders in AMD, DME, and RVO
  • [H5] Comparing Aflibercept 8 mg and Faricimab in RVO
  • [H5] Insights from Privotal Trials for Aflibercept (8 mg) in RVO
  • [H5] Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
  • [H5] Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases
  • [H5] Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
  • [H5] Evolving Therapeutic Strategies with Next-Generation Anti-VEGF Agents in Retinal Vascular Diseases
  • [H5] Clinical Insights Shaping Real-World Decision-Making in Geographic Atrophy
  • [H5] Managing Geographic Atrophy in a 90-Year-Old Patient with Coexisting Neovascular AMD and Recurrent CNV Activation
  • [H5] Evaluating Progressive Multifocal Geographic Atrophy in an Asymptomatic 81-Year-Old Male

Images

Abbiamo trovato 135 immagini in questa pagina web.

23 attributi alt sono vuoti o mancanti. Aggiungi testo alternativo in modo tale che i motori di ricerca possano comprendere meglio il contenuto delle tue immagini.

Text/HTML Ratio

Ratio : 3%

Il rapporto testo/codice HTML di questa pagina e inferiore a 15 percento, questo significa che il tuo sito web necessita probabilmente di molto piu contenuto.

Flash

Perfetto, non e stato rilevato contenuto Flash in questa pagina.

Iframe

Grande, non sono stati rilevati Iframes in questa pagina.

URL Rewrite

Buono. I tuoi links appaiono friendly!

Underscores in the URLs

Perfetto! Non sono stati rilevati underscores nei tuoi URLs.

In-page links

Abbiamo trovato un totale di 89 links inclusi 0 link(s) a files

Anchor Type Juice
All News Interno Passing Juice
Blogs Interno Passing Juice
All Videos Interno Passing Juice
Case-Based Roundtable Series Interno Passing Juice
Eichenbaum Acorns Interno Passing Juice
Expert Interviews Interno Passing Juice
Eyeviews Interno Passing Juice
Insights Interno Passing Juice
Medical World News Externo Passing Juice
Podcasts Interno Passing Juice
Rapid Readouts Interno Passing Juice
The Retina TL;DR Interno Passing Juice
Viewpoints Interno Passing Juice
Conference Coverage Interno Passing Juice
Conference Listing Interno Passing Juice
Modern Retina Digital Edition Interno Passing Juice
Supplements And Featured Publications Interno Passing Juice
Between the Lines Interno Passing Juice
CME/CE Interno Passing Juice
EYLEA 8mg for nAMD and DME Treatment Interno Passing Juice
Sponsored Resources Interno Passing Juice
Partners Interno Passing Juice
Subscribe Interno Passing Juice
AMD Interno Passing Juice
Wet AMD Interno Passing Juice
Biosimilar Interno Passing Juice
Diabetic Macular Edema Interno Passing Juice
Diabetic Eye Awareness Interno Passing Juice
Diabetic Retinopathy Interno Passing Juice
Geographic Atrophy Interno Passing Juice
Imaging Interno Passing Juice
Inherited Retinal Diseases Interno Passing Juice
Ophthalmology Interno Passing Juice
RVO Interno Passing Juice
Retina Technology Interno Passing Juice
Retinal Surgery Interno Passing Juice
Uveitis Interno Passing Juice
Geographic Atrophy Interno Passing Juice
ISS 2026 highlights advances in ophthalmic imaging for retinal practice Interno Passing Juice
FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic Interno Passing Juice
Treating MacTel: First identify patient candidates and appropriate eye selection Interno Passing Juice
A medical fellow finds some magic at the AAO Annual Meeting Interno Passing Juice
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight Interno Passing Juice
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease Interno Passing Juice
FLORetina 2025: Long-term follow-up in pediatric gene therapy Interno Passing Juice
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management Interno Passing Juice
FLORetina 2025: Reframing retinal disease through the lens of choroidal health Interno Passing Juice
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage Interno Passing Juice
Martin David Harp Interno Passing Juice
Christina Y. Weng, MD, MBA, FASRS Interno Passing Juice
View All Interno Passing Juice
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO Interno Passing Juice
Eichenbaum Acorns: Mentorship, momentum, and the making of a retina podcast Interno Passing Juice
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS Interno Passing Juice
The Retina TL;DR: Redefining office-based surgery for retina care with Jonathan Feistmann, MD Interno Passing Juice
Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME Interno Passing Juice
The Retina TL;DR: Rethinking retinal detachment repair with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD Interno Passing Juice
PHOTON Trial Outcomes: Impact on DME Patient Care in Clinical Practice Interno Passing Juice
PULSAR Study Findings: Implications for Treating nAMD in Clinical Practice Interno Passing Juice
Integrating AI to manage DR in a primary care setting Interno Passing Juice
What to expect from virtual AAO 2020 Interno Passing Juice
View More Interno Passing Juice
Navigating geographic atrophy from biomarkers to bilateral therapy Interno Passing Juice
8 things to know about aflibercept 8 mg for retinal vascular disease Interno Passing Juice
Inside the mindset of an early adopter Interno Passing Juice
Challenges for young physicians treating patients with GA Interno Passing Juice
AAO highlight: Looking ahead to 2026 Interno Passing Juice
How AI is reshaping ophthalmology in 2025 and beyond Interno Passing Juice
Seeing the difference: Multimodal imaging for AMD and GA Interno Passing Juice
Ryan Livingston Interno Passing Juice
Lynda Charters Interno Passing Juice
Kevin Kunzmann Interno Passing Juice
Jeffry D. Gerson, OD, FAAO Interno Passing Juice
Theodore Leng, MD, MS Interno Passing Juice
Sheryl Stevenson Interno Passing Juice
Joshua Mali, MD Interno Passing Juice
Arshad M. Khanani, MD, MA, FASRS Interno Passing Juice
Modern Retina Staff Reports Interno Passing Juice
Jayanth Sridhar, MD Interno Passing Juice
Matt Hoffman Interno Passing Juice
Sheila Setork, OD Interno Passing Juice
About Interno Passing Juice
Advertise Interno Passing Juice
Editorial Interno Passing Juice
Contact Us Interno Passing Juice
Terms and Conditions Interno Passing Juice
Privacy Interno Passing Juice
Do Not Sell My Personal Information Externo Passing Juice
Home Interno Passing Juice

SEO Keywords

Keywords Cloud

track management video fasrs cme more cope retinal faao view

Consistenza Keywords

Keyword Contenuto Title Keywords Description Headings
more 64
view 52
video 44
track 35
faao 24

Usabilita

Url

Dominio : modernretina.com

Lunghezza : 16

Favicon

Grande, il tuo sito usa una favicon.

Stampabilita

Non abbiamo riscontrato codice CSS Print-Friendly.

Lingua

Buono. La tua lingua dichiarata en.

Dublin Core

Questa pagina non sfrutta i vantaggi di Dublin Core.

Documento

Doctype

HTML 5

Encoding

Perfetto. Hai dichiarato che il tuo charset e UTF-8.

Validita W3C

Errori : 0

Avvisi : 0

Email Privacy

Attenzione! E stato trovato almeno un indirizzo mail in plain text. Usa antispam protector gratuito per nascondere gli indirizzi mail agli spammers.

Deprecated HTML

Grande! Non abbiamo trovato tags HTML deprecati nel tuo codice.

Suggerimenti per velocizzare

Eccellente, il tuo sito web non utilizza nested tables.
Molto male, il tuo sito web utilizza stili CSS inline.
Grande, il tuo sito web ha pochi file CSS.
Molto male, il tuo sito web ha troppi file JS (piu di 6).
Perfetto, il vostro sito si avvale di gzip.

Mobile

Mobile Optimization

Apple Icon
Meta Viewport Tag
Flash content

Ottimizzazione

XML Sitemap

Grande, il vostro sito ha una sitemap XML.

https://www.modernretina.com/sitemap.xml
https://www.modernretina.com/sitemap-news.xml

Robots.txt

https://modernretina.com/robots.txt

Grande, il vostro sito ha un file robots.txt.

Analytics

Grande, il vostro sito ha uno strumento di analisi dei dati.

   Google Analytics

PageSpeed Insights

Dispositivo
Categorie

Free SEO Testing Tool

Free SEO Testing Tool e uno strumento di ottimizzazione per i motori di ricerca (seo tool) che serve per analizzare le tue pagine web